Marks, Kristen

Publications

Sort by

Co-Author Network

selected publications

Immunogenicity and Safety of Hepatitis B vaccine with a Toll-like Receptor 9 Agonist Adjuvant (HEPLISAV-B) in HBV Vaccine-naive People with HIV. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023 Academic Article GET IT
Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant persons. American journal of obstetrics & gynecology MFM. 2022 Academic Article GET IT
Times cited: 2
Rapid Treatment Initiation for Hepatitis C Virus Infection: Potential Benefits, Current Limitations, and Real-World Examples. Gastroenterology & hepatology. 2022 Academic Article GET IT
Cost of providing co-located hepatitis C treatment at a syringe service program exceeds potential reimbursement: Results from a clinical trial. Drug and alcohol dependence reports. 2022 Academic Article GET IT
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. Annals of internal medicine. 2022 Academic Article GET IT
Times cited: 21
Rapid Treatment Initiation for Hepatitis C in Young People Who Inject Drugs: The Seek, Test, and Rapid Treatment Randomized Trial. Open forum infectious diseases. 2022 Academic Article GET IT
Accessible Hepatitis C Care for People Who Inject Drugs: A Randomized Clinical Trial. JAMA internal medicine. 2022 Academic Article GET IT
Times cited: 11
Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 Academic Article GET IT
Times cited: 53
The impact of COVID-19 on people who inject drugs in New York City: increased risk and decreased access to services. Harm reduction journal. 2021 Academic Article GET IT
Times cited: 25
Hepatitis C Treatment by Nonspecialist Providers in the Direct-acting Antiviral Era. Medical care. 2021 Academic Article GET IT
Elevated inflammatory markers are associated with poor outcomes in COVID-19 patients treated with remdesivir. Journal of medical virology. 2021 Academic Article GET IT
Times cited: 8
Medical provider stigma experienced by people who use drugs (MPS-PWUD): Development and validation of a scale among people who currently inject drugs in New York City. Drug and alcohol dependence. 2021 Academic Article GET IT
Times cited: 11
Remdesivir Treatment for Severe COVID-19 in Third-Trimester Pregnancy: Case Report and Management Discussion. Open forum infectious diseases. 2020 Academic Article GET IT
Times cited: 4334
Assessing routes of hepatitis C transmission in HIV-infected men who have sex with men using single genome sequencing. PloS one. 2020 Academic Article GET IT
Times cited: 5
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. The New England journal of medicine. 2020 Academic Article GET IT
Times cited: 914
Management of Hepatitis C in 2019. JAMA. 2019 Academic Article GET IT
Times cited: 12
Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019 Academic Article GET IT
Times cited: 13
Diagnosis and Genotyping of Coxiella burnetii Endocarditis in a Patient with Prosthetic Pulmonary Valve Replacement Using Next-Generation Sequencing of Plasma Microbial Cell-Free DNA. Open forum infectious diseases. 2019 Academic Article GET IT
Times cited: 19
Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial. Hepatology (Baltimore, Md.). 2019 Academic Article GET IT
Times cited: 14
Strategies for Improving Hepatitis C Treatment Access in the United States: State Officials Address High Drug Prices, Stigma, and Building Treatment Capacity. Journal of public health management and practice : JPHMP. 2019 Academic Article GET IT
Times cited: 12
Management of hepatitis B and C infections in rheumatologic disease. Best practice & research. Clinical rheumatology. 2018 Review GET IT
Times cited: 2
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. The Journal of antimicrobial chemotherapy. 2018 Academic Article GET IT
Times cited: 11
Hepatitis C Management Simplification From Test to Cure: A Framework for Primary Care Providers. Clinical therapeutics. 2018 Academic Article GET IT
Times cited: 28
Hepatitis C Treatment Outcomes for People Who Inject Drugs Treated in an Accessible Care Program Located at a Syringe Service Program. Open forum infectious diseases. 2018 Academic Article GET IT
Times cited: 35
Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials. Liver international : official journal of the International Association for the Study of the Liver. 2017 Academic Article GET IT
Times cited: 10
The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma. Alimentary pharmacology & therapeutics. 2017 Academic Article GET IT
Times cited: 15
Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention. PloS one. 2017 Academic Article GET IT
Times cited: 38
Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017 Academic Article GET IT
Times cited: 28
Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection. World journal of hepatology. 2017 Academic Article GET IT
Times cited: 2
Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES. Alimentary pharmacology & therapeutics. 2016 Academic Article GET IT
Times cited: 30
Herpes Simplex Virus Hepatitis in an Immunocompetent Host Resembling Hepatic Pyogenic Abscesses. Case reports in hepatology. 2016 Academic Article GET IT
Times cited: 19
Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES. Alimentary pharmacology & therapeutics. 2016 Academic Article GET IT
Times cited: 11
The Risk of Cardiovascular Disease, Diabetes, Liver-Related Outcomes, and Death Over 10 Years in HIV/HCV-Coinfected Patients With and Without Steatosis. AIDS research and human retroviruses. 2016 Academic Article GET IT
Times cited: 8
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology (Baltimore, Md.). 2015 Review GET IT
Times cited: 1003
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 396
Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239. Journal of acquired immune deficiency syndromes (1999). 2014 Academic Article GET IT
Times cited: 2
Fulminant and fatal encephalitis caused by Acanthamoeba in a kidney transplant recipient: case report and literature review. Transplant infectious disease : an official journal of the Transplantation Society. 2013 Review GET IT
Times cited: 30
Depression and fatigue in chronic hepatitis C patients with and without HIV co-infection. Psychosomatics. 2013 Academic Article GET IT
Times cited: 14
Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial. HIV clinical trials. 2013 Academic Article GET IT
Times cited: 6
Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. 2012 GET IT
Times cited: 53
The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir. Antiviral therapy. 2012 Review GET IT
Times cited: 29
Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood. 2011 Academic Article GET IT
Times cited: 151
Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance. Journal of viral hepatitis. 2010 Academic Article GET IT
Times cited: 49
Identification of substance use and dependence among patients with viral hepatitis. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2010 Academic Article GET IT
Times cited: 8
Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. Journal of acquired immune deficiency syndromes (1999). 2009 Academic Article GET IT
Times cited: 39
Autoimmune hepatitis in the HIV-infected patient: a therapeutic dilemma. 2009 GET IT
Times cited: 17
How effective is eltrombopag for the treatment of thrombocytopenia in patients with HCV infection?. Nature clinical practice. Gastroenterology & hepatology. 2008 Comment GET IT
Times cited: 2
Understanding the pathogenesis and management of hepatitis B/HIV and hepatitis B/hepatitis C virus coinfection. Clinics in liver disease. 2007 Review GET IT
Times cited: 15
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. Journal of hepatology. 2007 Academic Article GET IT
Times cited: 197
Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. The Journal of infectious diseases. 2005 Academic Article GET IT
Times cited: 74
New Antiretroviral Agents for the Treatment of HIV Infection. Current infectious disease reports. 2004 Academic Article GET IT
Times cited: 10
New antiretroviral agents for the treatment of HIV infection. Current HIV/AIDS reports. 2004 Review GET IT
Times cited: 6

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Research Training in Infectious Diseases awarded by National Institute of Allergy & Infectious Diseases Co-Investigator 2020 - 2025

Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials Unit awarded by National Institute of Allergy & Infectious Diseases Key Personnel 2020 - 2027

ACTG LOC: PF A5379 - Y3 Protocol co-Chair (1560 G YC257) awarded by National Cancer Institute Principal Investigator Subaward 2020 - 2027
1/2 REPRIEVE Extension for Trial Completion awarded by Breast Cancer Research Foundation, Inc. Principal Investigator Subaward 2023 - 2024
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) [UM1AI068636] - PF CRS 7804 awarded by National Cancer Institute Principal Investigator Subaward 2020 - 2023
CoVPN 3001: Phase 3, SARS-CoV-2 Vaccine (Moderna TX, Inc.) awarded by National Institute of Allergy & Infectious Diseases Principal Investigator Subaward 2020 - 2023
CoVPN 3004: Phase 3, SARS-CoV-2 Vaccine (Novavax) awarded by National Institute of Allergy & Infectious Diseases Principal Investigator Subaward 2020 - 2023
Pitavastatin to Reduce Physical Function Impairment and FRailty in HIV (PREPARE) - A5332 substudy A5361s: 1560 B WB699 awarded by National Cancer Institute Principal Investigator Subaward 2018 - 2023
A5332: Prevention of Vascular Events in HIV - REPRIEVE & Substudy A5333s: Pitavastatin on CAD & Inflammatory Biomarkers awarded by National Heart, Lung, & Blood Institute Principal Investigator Subaward 2014 - 2023

more ...

less ...

Background

education and training

M.S., Weill Cornell Graduate School of Medical Sciences 2009
M.D., Columbia University College of Physicians and Surgeons 1999
B.A., M.S., Stanford University 1995

Contact

full name

Kristen Marks

primary email

markskr@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Kristen Marks Associate Professor of Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage